Table 2.

International Task Force Criteria modified in 2010 (reproduced from 31 with permission)

Domain	Major criteria	Minor criteria
Family history	ARVD confirmed in a first‐degree relative ARVD confirmed at surgery or autopsy in a first‐degree relative Pathogenetic mutation in a gene associated with ARVD	History of ARVD in a first‐degree relative in whom it was not possible to determine whether the current Task Force Criteria is met Premature death at <35 years of age due to suspected ARVD ARVD confirmed pathologically or by current Task Force criteria in a second‐degree relative
ECG abnormalities	Epsilon wave (reproducible low‐amplitude signals between end of QRS complex and beginning of T‐wave in leads V1 to V3 Inverted T‐waves in leads V1 to V3 in individuals >14 years of age in the absence of RBBB and QRS ≥120 ms)	Late potentials by signal‐averaged ECG in ≥1 of 3 parameters in an absence of QRS ≥110 ms Filtered QRS duration ≥114 ms Duration of terminal QRS <40 μV and ≥38 ms Root‐mean‐square voltage of terminal QRS <40 ms and ≤20 μV Terminal activation duration of QRS ≥55 ms measured between the nadir of the S wave and the end of the QRS complex, including R', in V1, V2, or V3, without RBBB T‐wave inversion in V1 and V2 in individuals >14 years of age in an absence of RBBB, or in V4 to V6 T‐wave inversion in leads V1 to V4 in individuals >14 years of age in the presence of complete RBBB
Arrhythmias	Nonsustained or sustained VT with a LBBB morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in aVL)	Nonsustained or sustained VT of RVOT configuration, LBBB morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in aVL) or of unknown axis 500 ventricular extrasystoles within 24 h on Holter monitoring
Tissue characteristics	Fibro‐fatty replacement of the myocardium on endomyocardial biopsy	Residual myocytes <60% by morphometric analysis (or <50% if estimated) with fibrous replacement of the RV free wall myocardium in >1 sample, with or without fatty replacement of tissue on endomyocardial biopsy Residual myocytes 60%‐75% morphometric analysis (or 50%‐65% if estimated) with fibrous replacement of the RV free wall myocardium in >1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
Global or regional functional or structural abnormalities
Echocardiography	Regional RV akinesia, dyskinesia, or aneurysm and one of the following at end diastole: ○PLAX RVOT ≥32 mm (corrected for body size [PLAX/BSA] ≥19 mm/m2) ○PLAX RVOT ≥36 mm (corrected for body size [PLAX/BSA] ≥21 mm/m2) ○Fractional area change ≤33%	Regional RV akinesia, dyskinesia, and one of the following at end diastole: ○PLAX RVOT ≥32 and <36 mm (corrected for body size [PLAX/BSA] >18 and <21 mm/m2) ○PLAX RVOT ≥29 and <32 mm (corrected for body size [PLAX/BSA] >16 and <19 mm/m2) ○Fractional area change >33% and ≤40%
MRI	Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and one of the following: ○Ratio of RV end‐diastolic volume to BSA ≥110 mL/m2 (male) or ≥100 mL/m2 (female) ○RV ejection fraction ≤40%	Regional RV akinesia or dyskinesia and one of the following: ○Ratio of RV end‐diastolic volume to BSA ≥100 mL/m2 and <110 mL/m2 (male) or ≥90 mL/m2 and <100 mL/m2 (female) ○RV ejection fraction >40% and ≤45%
RV angiography	Regional RV akinesia, dyskinesia, or aneurysm	Regional RV akinesia, dyskinesia, or aneurysm